Clinical trials: Priming
HIV Infections
Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa
The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.
- Trial name
- NCT01927835
- Testing
- DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Poliomyelitis
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding, and genetic stability of two novel oral polio vaccine type 2 (nOPV2) vaccine candidates in IPV-primed…
- Trial name
- nOPV2M4a (NCT03430349)
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme
HIV
Thai Prophylactic HIV Vaccine Phase I Study
The development of a safe and effective vaccine for HIV is the subject of intensive world-wide research. Various approaches are being investigated in monkey models and humans.
- Trial name
- NCT00333424
- Testing
- pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine
- Where
- Thailand
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Nipah Virus Infection
Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects.
- Trial name
- NCT06221813
- Testing
- PHV02, Lactated Ringer's
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
HIV Infections
Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly in prime-boost regimens in HIV-uninfected, healthy…
- Trial name
- NCT01705990
- Testing
- SeV-G(NP) (0.2mL, 2x10^7 CIU), SeV-G(NP) (0.2mL, 2x10^8 CIU), Ad35-GRIN (0.5mL)
- Where
- 3 sites in Kenya, Rwanda and 1 more
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Innate Immune Response, Immune Tolerance
The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response
To evaluate the bacterial-viral interactions between LPS and Fluenz as a model for sepsis (bacterial) and Influenza (viral) infections which are common and associated with high mortality rates in the ICU.
- Trial name
- LPS-Fluenz (NCT02642237)
- Testing
- Fluenz, LPS
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
HIV-1-infection
A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV
This is a randomized open-label trial to examine the safety and immunogenicity of INO-6160 (synthetic DNAs encoding a native-like HIV Env Trimer and Interleukin-12), alone or in a prime-boost regimen with VRC HIV Env Trimer 4571…
- Trial name
- NCT05828095
- Testing
- INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
PRIBIVAC will assess a heterologous prime-boost-boost strategy in comparison with a homologous regimen in order to compare short and long-term immunogenicity of different COVID-19 vaccine combinations against the ancestral…
- Trial name
- PRIBIVAC (NCT05142319)
- Testing
- Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN
- Where
- Singapore
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Influenza
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04
This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.
- Trial name
- NCT00814385
- Testing
- Aflunov (Single prime, single boost), Aflunov (Double prime, single boost), Aflunov (No prime, single boost)
- Where
- 2 sites in United Kingdom
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Healthy
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and of a late boost vaccination; and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine…
- Trial name
- IPCAVD-012 (NCT02935686)
- Testing
- Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant
- Where
- 13 sites in United States, Kenya and 1 more
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Hepatitis B, Acellular Pertussis
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal…
- Conditions
- Hepatitis B, Acellular Pertussis, Tetanus, Poliomyelitis
- Trial name
- NCT00463437
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Infanrix hexa
- Where
- 63 sites in Germany, Poland and 1 more
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
This is a Phase I study whose primary outcome is to assess the safety of a new tuberculosis vaccine, FP85A, when administered individually and sequentially with MVA85A in a prime-boost regime, to healthy volunteers, who have…
- Trial name
- NCT00653770
- Testing
- FP85A, MVA85A
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infections, Streptococcal
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination…
- Trial name
- NCT00985465
- Testing
- Pneumococcal vaccine GSK1024850A
- Where
- Mali
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Haemophilus Influenzae Type b, Tetanus
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.
The purpose of the study is as follows: To evaluate the persistence of antibodies and the presence of immune memory induced by a 3-dose primary vaccination with Tritanrix™-HepB/Hib-MenAC (three formulations) in the study…
- Conditions
- Haemophilus Influenzae Type b, Tetanus, Whole Cell Pertussis, Hepatitis B
- Trial name
- NCT00317174
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- Philippines
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
PRIME Follow up - Quadri Meningo Vacinees
A previous cohort of 93 clinical trial participants received quadrivalent meningococcal conjugate vaccine, which includes strains ACW and Y, in their teenage years.
- Trial name
- PRIMEfollowup (NCT02811120)
- Testing
- venepuncture only
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Public Health England
Athletic Performance
Priming Magnitude and Retention in Highly Trained Male Volleyball Players
This study examined whether a short, high-intensity isometric exercise can influence physical performance and muscle characteristics several hours after it is performed.
- Trial name
- NCT07483931
- Testing
- Isometric Conditioning Activity (ICA), Volleyball-Specific Warm-Up (Control Condition)
- Where
- Poland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- The Jerzy Kukuczka Academy of Physical Education in Katowice
Coronavirus, SARS-CoV-2 Infection
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2
This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
- Conditions
- Coronavirus, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT05113862
- Testing
- LD Vehicle-GNP, LD PepGNP-Covid19, HD Vehicle-GNP
- Where
- Switzerland
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gylden Pharma Ltd
Neisseria Meningitidis
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine.
- Trial name
- NCT07197762
- Testing
- Trumenba, PENBRAYA
- Where
- 2 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
This study will determine the safety and side effects of two experimental HIV vaccines given in a "prime-boost" schedule. It will also monitor participants for the social impact of being in an HIV vaccine study (e.g., problems…
- Trial name
- NCT00109629
- Testing
- VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Self Report, Questionnaire Design
Eye Examinations as a Gold Standard to Evaluating Survey Instruments
Objective measures of health are relatively expensive; meanwhile, self-reports are critiqued to be subjective and not comparable. A middle ground approach is to apply the frontier work of vignette methods.
- Trial name
- NCT02244060
- Testing
- Priming effect from vignette
- Where
- China
- Volunteers
- 4,320 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)